
Neuropace, Inc.: shareholders and insiders
Price
$8.15
November 18, 2026Market cap $274M
What Ploutos Investor adds for Neuropace
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 32% since Nov 12, 2026, when the 10-Q these figures come from was filed ($12.02 then, $8.20 on Nov 17, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 18, 2025 to Nov 17, 2026, from their own Form 4 filings.
Bought on the market
$198.4K
2 people
Sold on the market
$399.3K
1 person
From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $198.4K by 2 people·no sales
- 2025: no buys, sold $399.3K by 1 person
- 2026: bought $198.4K by 2 people, no sales
- Nov 17, 2026Patrick F. WilliamsChief Financial OfficerKind
- Nov 17, 2026Joel BeckerCHIEF EXECUTIVE OFFICERKind
- Sep 24, 2026Martha MorrellCHIEF MEDICAL OFFICERKind
- Sep 20, 2026Patrick F. WilliamsChief Financial OfficerKind
- Sep 3, 2026Joel BeckerCHIEF EXECUTIVE OFFICERKind
- Aug 27, 2026Joel BeckerCHIEF EXECUTIVE OFFICERKind
- Aug 27, 2026Martha MorrellCHIEF MEDICAL OFFICERKind
- Jun 24, 2026Martha MorrellCHIEF MEDICAL OFFICERKind
- Jun 19, 2026Uri GeigerDirectorKind
- Jun 19, 2026Frank M FischerDirectorKind
- Jun 19, 2026Rakhi KumarDirectorKind
- Jun 5, 2026R Scott HuennekensDirectorKind
- Jun 5, 2026Frank M FischerDirectorKind
- Jun 5, 2026Uri GeigerDirectorKind
- Jun 5, 2026Rakhi KumarDirectorKind
- Jun 5, 2026Renee RyanDirectorKind
- Jun 5, 2026Lisa AndradeDirectorKind
- Jun 3, 2026Joel BeckerCHIEF EXECUTIVE OFFICERKind
- May 27, 2026Joel BeckerCHIEF EXECUTIVE OFFICERKind
- May 27, 2026Martha MorrellCHIEF MEDICAL OFFICERKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Patrick F. WilliamsChief Financial Officer | 11.9K | $8.34 | $99.1K | Form 4 | |
| Nov 17, 2026 | Joel BeckerCHIEF EXECUTIVE OFFICER | 11.9K | $8.35 | $99.3K | Form 4 | |
| Sep 24, 2026 | Martha MorrellCHIEF MEDICAL OFFICER | 335 | $13.97 | $4.7K | Form 4 | |
| Sep 20, 2026 | Patrick F. WilliamsChief Financial Officer | 1,162 | $14.28 | $16.6K | Form 4 | |
| Sep 3, 2026 | Joel BeckerCHIEF EXECUTIVE OFFICER | 1,310 | $14.75 | $19.3K | Form 4 | |
| Aug 27, 2026 | Joel BeckerCHIEF EXECUTIVE OFFICER | 1,126 | $14.13 | $15.9K | Form 4 | |
| Aug 27, 2026 | Martha MorrellCHIEF MEDICAL OFFICER | 358 | $14.13 | $5.1K | Form 4 | |
| Jun 24, 2026 | Martha MorrellCHIEF MEDICAL OFFICER | 335 | $16.22 | $5.4K | Form 4 | |
| Jun 19, 2026 | Uri GeigerDirector | 789 | $15.63 | $12.3K | Form 4 | |
| Jun 19, 2026 | Frank M FischerDirector | 1,467 | $15.63 | $22.9K | Form 4 | |
| Jun 19, 2026 | Rakhi KumarDirector | 989 | $15.63 | $15.5K | Form 4 | |
| Jun 5, 2026 | R Scott HuennekensDirector | 2,890 | – | – | Form 4 | |
| Jun 5, 2026 | Frank M FischerDirector | 2,890 | – | – | Form 4 | |
| Jun 5, 2026 | Uri GeigerDirector | 2,890 | – | – | Form 4 | |
| Jun 5, 2026 | Rakhi KumarDirector | 2,890 | – | – | Form 4 | |
| Jun 5, 2026 | Renee RyanDirector | 2,890 | – | – | Form 4 | |
| Jun 5, 2026 | Lisa AndradeDirector | 2,890 | – | – | Form 4 | |
| Jun 3, 2026 | Joel BeckerCHIEF EXECUTIVE OFFICER | 1,255 | $15.88 | $19.9K | Form 4 | |
| May 27, 2026 | Joel BeckerCHIEF EXECUTIVE OFFICER | 1,126 | $17.06 | $19.2K | Form 4 | |
| May 27, 2026 | Martha MorrellCHIEF MEDICAL OFFICER | 358 | $17.06 | $6.1K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 28, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by NPCE's officers and directors from 2021 up to November 17, 2025, 5 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- First Light Asset Management, LLCwith 1 more personShare of class12.3%
- Polar Capital Holdings Plcwith 1 more personShare of class9.13%
- Soleus Private Equity Fund I, L.P.with 8 more personsShare of class8.90%
- Morgan Stanleywith 1 more personShare of class8.30%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| First Light Asset Management, LLCwith 1 more person | 12.3% | 4.20M | Sep 4, 20262 filings since May 15, 2026 | 13G/A | |
| Polar Capital Holdings Plcwith 1 more person | 9.13% | 2.97M | May 15, 2025 | 13G | |
| Soleus Private Equity Fund I, L.P.with 8 more persons | 8.90% | 2.96M | Nov 7, 20252 filings since Aug 5, 2025 | 13G/A | |
| Morgan Stanleywith 1 more person | 8.30% | 2.49M | Feb 4, 2025 | 13G/A |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+48%
- Millennium Mgmt (Englander)In the quarter-25%
- D.E. ShawIn the quarter+269%
- Renaissance TechnologiesIn the quarter-61%
- AQR CapitalIn the quarter+28%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | – | – | 0.00% | |
| Citadel Advisors (Griffin) | 128.8K | +48% | $2.0M | 0.00% |
| Millennium Mgmt (Englander) | 30.6K | -25% | $500.0K | 0.00% |
| D.E. Shaw | 161.1K | +269% | $2.6M | 0.00% |
| Renaissance Technologies | 43.7K | -61% | $600.0K | 0.00% |
| AQR Capital | 35.9K | +28% | $600.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 2.63% of its shares outstanding were held short, -1.9% since the report before.
- Shares held short
- 886.2K
- 2.63%
- Since the report before903.6K on Sep 30, 2026
- -1.9%
- 8.3
- 107.1K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 85%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 395.6K
- Nov 15, 2023: Shares held short 151.0K
- Nov 30, 2023: Shares held short 128.8K
- Dec 15, 2023: Shares held short 94.1K
- Dec 29, 2023: Shares held short 63.5K
- Jan 12, 2024: Shares held short 35.8K
- Jan 31, 2024: Shares held short 63.0K
- Feb 15, 2024: Shares held short 62.7K
- Feb 29, 2024: Shares held short 50.3K
- Mar 15, 2024: Shares held short 30.9K
- Mar 28, 2024: Shares held short 85.9K
- Apr 15, 2024: Shares held short 97.1K
- Apr 30, 2024: Shares held short 89.8K
- May 15, 2024: Shares held short 125.5K
- May 31, 2024: Shares held short 74.2K
- Jun 14, 2024: Shares held short 86.7K
- Jun 28, 2024: Shares held short 135.8K
- Jul 15, 2024: Shares held short 439.7K
- Jul 31, 2024: Shares held short 478.3K
- Aug 15, 2024: Shares held short 488.3K
- Aug 30, 2024: Shares held short 517.8K
- Sep 13, 2024: Shares held short 506.4K
- Sep 30, 2024: Shares held short 532.8K
- Oct 15, 2024: Shares held short 509.2K
- Oct 31, 2024: Shares held short 437.9K
- Nov 15, 2024: Shares held short 290.4K
- Nov 29, 2024: Shares held short 249.4K
- Dec 13, 2024: Shares held short 251.4K
- Dec 31, 2024: Shares held short 263.3K
- Jan 15, 2025: Shares held short 267.0K
- Jan 31, 2025: Shares held short 219.4K
- Feb 14, 2025: Shares held short 228.0K
- Feb 28, 2025: Shares held short 245.6K
- Mar 14, 2025: Shares held short 308.3K
- Mar 31, 2025: Shares held short 449.6K
- Apr 15, 2025: Shares held short 347.5K
- Apr 30, 2025: Shares held short 393.7K
- May 15, 2025: Shares held short 400.5K
- May 30, 2025: Shares held short 355.8K
- Jun 13, 2025: Shares held short 356.7K
- Jun 30, 2025: Shares held short 782.3K
- Jul 15, 2025: Shares held short 896.5K
- Jul 31, 2025: Shares held short 1.11M
- Aug 15, 2025: Shares held short 997.5K
- Aug 29, 2025: Shares held short 1.01M
- Sep 15, 2025: Shares held short 944.9K
- Sep 30, 2025: Shares held short 1.12M
- Oct 15, 2025: Shares held short 1.08M
- Oct 31, 2025: Shares held short 957.8K
- Nov 14, 2025: Shares held short 992.7K
- Nov 28, 2025: Shares held short 950.3K
- Dec 15, 2025: Shares held short 936.6K
- Dec 31, 2025: Shares held short 866.2K
- Jan 15, 2026: Shares held short 893.7K
- Jan 30, 2026: Shares held short 791.6K
- Feb 13, 2026: Shares held short 869.3K
- Feb 27, 2026: Shares held short 805.2K
- Mar 13, 2026: Shares held short 939.0K
- Mar 31, 2026: Shares held short 948.8K
- Apr 15, 2026: Shares held short 916.8K
- Apr 30, 2026: Shares held short 773.8K
- May 15, 2026: Shares held short 613.8K
- May 29, 2026: Shares held short 582.9K
- Jun 15, 2026: Shares held short 612.8K
- Jun 30, 2026: Shares held short 898.6K
- Jul 15, 2026: Shares held short 874.3K
- Jul 31, 2026: Shares held short 822.1K
- Aug 14, 2026: Shares held short 845.4K
- Aug 31, 2026: Shares held short 911.4K
- Sep 15, 2026: Shares held short 956.2K
- Sep 30, 2026: Shares held short 903.6K
- Oct 15, 2026: Shares held short 886.2K
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading55.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 55.5% of the shares in the reported trades were short sales, against 44.5% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 55.5%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 44.5%
- Change
- +11.0 pts
- Short sales a dayon average, of 228.6K shares
- 126.8K
- More than atof 3,666 US-listed companies, same days
- 69%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 55.1%
- Oct 12, 2026: Short sales 28.5%
- Oct 13, 2026: Short sales 56.4%
- Oct 14, 2026: Short sales 31.9%
- Oct 15, 2026: Short sales 55.6%
- Oct 16, 2026: Short sales 21.9%
- Oct 19, 2026: Short sales 49%
- Oct 20, 2026: Short sales 56.7%
- Oct 21, 2026: Short sales 63%
- Oct 22, 2026: Short sales 31.9%
- Oct 23, 2026: Short sales 64.2%
- Oct 26, 2026: Short sales 60.1%
- Oct 27, 2026: Short sales 35.2%
- Oct 28, 2026: Short sales 38.6%
- Oct 29, 2026: Short sales 60.8%
- Oct 30, 2026: Short sales 34.5%
- Nov 2, 2026: Short sales 39.4%
- Nov 3, 2026: Short sales 49.5%
- Nov 4, 2026: Short sales 41.4%
- Nov 5, 2026: Short sales 41.4%
- Nov 6, 2026: Short sales 56.5%
- Nov 9, 2026: Short sales 67.6%
- Nov 10, 2026: Short sales 57.2%
- Nov 11, 2026: Short sales 44.3%
- Nov 12, 2026: Short sales 44.3%
- Nov 13, 2026: Short sales 59%
- Nov 16, 2026: Short sales 46.9%
- Nov 17, 2026: Short sales 54.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Uri GeigerDirectorDirectly4.45M
- OrbiMed Capital GP VI LLCTenPercentOwnerDirectly–
- Orbimed Advisors LlcTenPercentOwnerDirectly–
- Frank M FischerDirectorDirectly599.5K
- Joel BeckerCHIEF EXECUTIVE OFFICERDirectly149.9K
- Patrick F. WilliamsChief Financial OfficerDirectly79.4K
- Martha MorrellCHIEF MEDICAL OFFICERDirectly51.4K
- Rakhi KumarDirectorDirectly23.0K
- R Scott HuennekensDirectorDirectly2,890
- Renee RyanDirectorDirectly2,890
- Lisa AndradeDirectorDirectly2,890
- Kck Ltd.TenPercentOwnerDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Uri GeigerDirector | 4.45M | – | Jun 19, 2026 | Form 4 |
| OrbiMed Capital GP VI LLCTenPercentOwner | – | 3.50M | Apr 18, 2024 | Form 4 |
| Orbimed Advisors LlcTenPercentOwner | – | 3.27M | May 14, 2025 | Form 4 |
| Frank M FischerDirector | 599.5K | – | Jun 19, 2026 | Form 4 |
| Joel BeckerCHIEF EXECUTIVE OFFICER | 149.9K | – | Nov 17, 2026 | Form 4 |
| Patrick F. WilliamsChief Financial Officer | 79.4K | – | Nov 17, 2026 | Form 4 |
| Martha MorrellCHIEF MEDICAL OFFICER | 51.4K | – | Sep 24, 2026 | Form 4 |
| Rakhi KumarDirector | 23.0K | – | Jun 19, 2026 | Form 4 |
| R Scott HuennekensDirector | 2,890 | – | Jun 5, 2026 | Form 4 |
| Renee RyanDirector | 2,890 | – | Jun 5, 2026 | Form 4 |
| Lisa AndradeDirector | 2,890 | – | Jun 5, 2026 | Form 4 |
| Kck Ltd.TenPercentOwner | – | – | Feb 20, 2025 | Form 4 |
A lower bound: it counts only the 12 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.09%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.03%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- IWViShares Russell 3000 ETFWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
7 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 80
- Q4 2025: Managers 100
- Q1 2026: Managers 115
- Q2 2026: Managers 113
Institutional investors by quarter
The fund managers holding NPCE, quarter by quarter, from Q2 2021 to Q2 2025, 17 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 113 managers held 26.58M shares, worth $422M. During the quarter 19 opened a position, 21 closed one, 46 added and 36 trimmed.
The largest holders, Q2 2026
- Polar Capital HoldingsIn the quarter
- Soleus Capital ManagementIn the quarter-0.7%
- First Light Asset ManagementIn the quarter+16%
- Morgan StanleyIn the quarter+3.4%
- BlackRockIn the quarter+5.6%
- Orbimed AdvisorsIn the quarter-28%
- Driehaus Capital ManagementIn the quarter-0.3%
- Vanguard Capital ManagementIn the quarter+9.2%
- Deutsche Bank Ag\In the quarter+0.7%
- Armistice CapitalIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Polar Capital Holdings | 3.30M | $52M | |
| Soleus Capital Management | 2.91M | -0.7% | $46M |
| First Light Asset Management | 2.86M | +16% | $45M |
| Morgan Stanley | 2.65M | +3.4% | $42M |
| BlackRock | 2.48M | +5.6% | $39M |
| Orbimed Advisors | 1.51M | -28% | $24M |
| Driehaus Capital Management | 1.45M | -0.3% | $23M |
| Vanguard Capital Management | 1.23M | +9.2% | $19M |
| Deutsche Bank Ag\ | 938.9K | +0.7% | $15M |
| Armistice Capital | 692.0K | $11M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Neuropace's filings show?
Who buys and sells is one part of Neuropace's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have NPCE's insiders bought or sold?
From May 28, 2026 to Nov 17, 2026 Neuropace's insiders bought $198.4K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Which well-known managers hold NPCE?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $2.6M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.